Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trilaciclib + rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone
- Development stage
- Unknown
- Lead developer
- G1 Therapeutics
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination therapy consisting of trilaciclib (a CDK 4/6 inhibitor) with R-CHOP (rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone). Trilaciclib is designed to protect hematopoietic stem cells from chemotherapy-induced myelosuppression by temporarily arresting these cells during chemotherapy exposure. R-CHOP is a standard immunochemotherapy regimen for non-Hodgkin's lymphoma, particularly diffuse large B-cell lymphoma (DLBCL). The combination aims to maintain the efficacy of R-CHOP while reducing chemotherapy-induced myelosuppression.
02
Targets
CD20 (B-lymphocyte antigen CD20)CDK6 (Cyclin-dependent kinase 6)TOP2A (DNA topoisomerase II)GR (Glucocorticoid receptor)CDK4 (Cyclin-dependent kinase 4)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on trilaciclib + rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trilaciclib + rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone.